Axsome Therapeutics (NASDAQ:AXSM) Director Roger Jeffs Sells 286 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Roger Jeffs sold 286 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the transaction, the director owned 58,653 shares in the company, valued at $14,439,195.54. This trade represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $253.77 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The firm has a market capitalization of $13.06 billion, a PE ratio of -68.03 and a beta of 0.61. The business’s 50-day moving average price is $209.27 and its 200-day moving average price is $181.43. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $257.44.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. The business’s revenue for the quarter was up 57.4% on a year-over-year basis. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP raised its stake in Axsome Therapeutics by 8.5% during the first quarter. Seven Fleet Capital Management LP now owns 14,055 shares of the company’s stock valued at $2,376,000 after buying an additional 1,100 shares during the last quarter. Perceptive Advisors LLC increased its holdings in shares of Axsome Therapeutics by 0.7% in the 1st quarter. Perceptive Advisors LLC now owns 149,950 shares of the company’s stock worth $25,345,000 after purchasing an additional 1,050 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Axsome Therapeutics by 26.1% in the 1st quarter. Janus Henderson Group PLC now owns 19,052 shares of the company’s stock worth $3,219,000 after purchasing an additional 3,948 shares in the last quarter. Amundi bought a new stake in shares of Axsome Therapeutics in the first quarter worth $498,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Axsome Therapeutics by 48.0% in the first quarter. EverSource Wealth Advisors LLC now owns 512 shares of the company’s stock worth $87,000 after acquiring an additional 166 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AXSM. Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Needham & Company LLC raised their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research report on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on Axsome Therapeutics in a research report on Tuesday, May 5th. Finally, Wolfe Research started coverage on Axsome Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $256.79.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.